Document Detail

Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.
MedLine Citation:
PMID:  20179909     Owner:  NLM     Status:  MEDLINE    
RATIONALE: Latent inhibition (LI) is the poorer conditioning to a stimulus seen when conditioning is preceded by repeated non-reinforced pre-exposure to the stimulus. LI indexes the ability to ignore irrelevant stimuli and is used extensively to model attentional impairments in schizophrenia. We showed that the pro-psychotic muscarinic antagonist scopolamine can produce LI disruption or LI persistence depending on dose and stage of administration: low doses disrupt LI acting in the pre-exposure stage of the LI procedure, whereas higher dose produces abnormally persistent LI via action in the conditioning stage. The two LI abnormalities show distinct response to antipsychotic drugs (APDs), with LI disruption, but not LI persistence, reversed by APDs. OBJECTIVES: The objective of this study is to show that both LI abnormalities will be reversed by the cognitive enhancers, glycine and physostigmine, in a stage-specific manner, reversing each abnormality via the stage at which it is induced by scopolamine. METHODS: LI was measured in a conditioned emotional response procedure. Scopolamine, physostigmine, and glycine were administered in pre-exposure and/or in conditioning. RESULTS: Scopolamine (0.15 mg/kg)-induced disrupted LI was reversed by glycine (800 mg/kg) and physostigmine (0.15 mg/kg) via action in pre-exposure, whereas scopolamine (1.5 mg/kg)-induced persistent LI was reversed by these compounds via action in conditioning. In addition, glycine reversed scopolamine-induced disrupted LI via action in conditioning. Finally, glycine failed to reverse amphetamine-induced disrupted LI. CONCLUSIONS: These results extend the pharmacological differentiation between scopolamine-induced disrupted and persistent LI and indicate that the scopolamine LI model may have a unique capacity to discriminate between typical APDs, atypical APDs, and cognitive enhancers.
Segev Barak; Ina Weiner
Related Documents :
21613759 - Comparison of intensity modulated radiotherapy and dynamic three-dimensional conformal ...
25468699 - Effect of the dose of exogenous fibrolytic enzyme preparations on preingestive fiber hy...
24436389 - Cross generation plasticity in cold hardiness is associated with diapause, but not the ...
21596489 - Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided...
1293959 - Hippocampal rhythmic slow activity (rsa) in the cat after intraseptal injections of mus...
3125719 - Individually-determined differences in the effects of psychotropic drugs on memory (exp...
1189879 - A rational approach to dosage and preparation of parenteral glucocorticoid substitution...
1725079 - Hypertensive crisis from chronic intoxication with nasal decongestant and cough medicat...
11425339 - Control of red fox (vulpes vulpes) fertility with cabergoline: dose response and timing...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-24
Journal Detail:
Title:  Psychopharmacology     Volume:  209     ISSN:  1432-2072     ISO Abbreviation:  Psychopharmacology (Berl.)     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-05     Completed Date:  2010-05-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608025     Medline TA:  Psychopharmacology (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  175-84     Citation Subset:  IM    
Department of Psychology, Tel-Aviv University, Tel-Aviv 69978, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amphetamine / pharmacology
Behavior, Animal / drug effects*
Cholinesterase Inhibitors / pharmacology*
Conditioning (Psychology) / drug effects*
Dose-Response Relationship, Drug
Glycine / pharmacology*
Models, Animal
Muscarinic Antagonists / pharmacology*
Nootropic Agents / pharmacology*
Physostigmine / pharmacology*
Rats, Wistar
Reaction Time / drug effects*
Scopolamine / pharmacology*
Reg. No./Substance:
0/Cholinesterase Inhibitors; 0/Muscarinic Antagonists; 0/Nootropic Agents; 300-62-9/Amphetamine; 51-34-3/Scopolamine; 56-40-6/Glycine; 57-47-6/Physostigmine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement...
Next Document:  Rapid determination of lithium in serum samples by capillary electrophoresis.